Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban.
Nicolás ManitoJosé María Cepeda-RodrigoNuria FarréMiguel Castillo OriveEnrique GalveJavier Jimenez-CandilJosé M García-PinillaEduardo Sebastián López SánchezCarles RafolsJuan José Gómez DoblasPublished in: Clinical cardiology (2023)
Approximately one out of four patients with HF and AF treated with rivaroxaban developed a HF worsening episode after 2 years of follow-up. The identification of those factors that increase the risk of HF worsening could be helpful in the comprehensive management of this population.